ArticleAsian Pacific journal of cancer prevention : APJCP2022
Reliability and Validity of the EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale) among Thai Women with Breast Cancer Undergoing Taxane-Based Chemotherapy.
Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Assessment tools for peripheral neuropathy in multiple myeloma.The Korean journal of internal medicine · 2026Pooled it
- Efficacy of Exercise on Severity of Paclitaxel-Induced Peripheral Neuropathy and Improving Quality of Life in Women with Non-metastatic Breast Cancer: Results of an Interim Analysis from an Ongoing Randomized Clinical Trial (ExPIN Trial).Integrative cancer therapiesTrial
- Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study.Frontiers in pharmacology · 2026Article
- Longitudinal patient-reported outcomes and predictors of improvement in chemotherapy-induced peripheral neuropathy a secondary analysis of a randomized trial.Frontiers in pharmacology · 2026Article
- The therapeutic effect of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy: a randomized controlled trial.Frontiers in oncology · 2025Article
- Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.BMC gastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-item scale (EORTC QLQ-CIPN20) is the common method for determining taxane-induced peripheral neuropathy (TIPN) symptoms. However, there have been no studies on the psychometric properties of the Thai Version of EORTC QLQ-CIPN20. The aim of this study was to evaluate the test-retest reliability, concurrent validity, and contrasting group validity of the Thai Version of EORTC QLQ-CIPN20 among women with breast cancer who received taxane-based chemotherapy.
methodsTwenty-eight breast cancer patients and 28 healthy controls participated in the study. Internal consistency, test-retest reliability, and inter-rater reliability were assessed using Cronbach α and the intraclass correlation coefficient (ICC). Concurrent validity was assessed via the Spearman correlation coefficient of the total scale of the EORTC QLQ-CIPN20 and the Total Neuropathy Score clinical version (TNSc), and contrasting group validity was assessed via the Mann-Whitney U test.
resultsThe internal consistency, test-retest reliability, and inter-rater reliability of the Thai Version of EORTC QLQ-CIPN20 was high to excellent (Cronbach α = 0.89, ICC = 0.84-0.95 and 0.78-0.94, respectively). However, the concurrent validity between the Thai Version of EORTC QLQ-CIPN20 and TNSc was not considered statistically significant. Contrasting group validity demonstrated statistically significant differences between breast cancer patients and healthy controls.
conclusionsThe results support that the Thai Version of EORTC QLQ-CIPN20 is reliable and valid in measuring TIPN symptoms in Thai women with breast cancer. The findings suggest that the Thai Version of EORTC QLQ-CIPN20 may be used to distinguish TIPN symptoms between healthy controls and women with breast cancer undergoing taxane-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.